Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) FCF Margin (2016 - 2025)

Historic FCF Margin for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to 29.11%.

  • CorMedix's FCF Margin rose 1483400.0% to 29.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.73%, marking a year-over-year increase of 4032600.0%. This contributed to the annual value of 116.7% for FY2024, which is 1130650900.0% down from last year.
  • CorMedix's FCF Margin amounted to 29.11% in Q3 2025, which was up 1483400.0% from 75.42% recorded in Q2 2025.
  • CorMedix's 5-year FCF Margin high stood at 176630.4% for Q1 2024, and its period low was 89069.3% during Q3 2022.
  • For the 5-year period, CorMedix's FCF Margin averaged around 266.64%, with its median value being 4670.76% (2021).
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 2000000000bps in 2023, then crashed by -1765799300bps in 2025.
  • CorMedix's FCF Margin (Quarter) stood at 11522.1% in 2021, then crashed by -84bps to 21155.46% in 2022, then soared by 661bps to 118603.6% in 2023, then plummeted by -100bps to 18.02% in 2024, then surged by 262bps to 29.11% in 2025.
  • Its last three reported values are 29.11% in Q3 2025, 75.42% for Q2 2025, and 50.47% during Q1 2025.